Horseshoe crabs, Limulus polyphemus, evolved 450 million years ago. They most commonly found in the soft, sandy,
muddy bottom of the east coast. Although
they are commonly called crabs, they are more closely related to
arachnids. The population of horseshoe
crabs along the Atlantic coast of the United States is listed as
threatened. While not listed as
endangered yet, the population numbers have been consistently dropping year
after year. This is due to human
predation and climate change. The main
prey of the horseshoe crab is shellfish and the fishermen along New England
coast are concerned with the amount of shellfish the horseshoe crabs eat in
respect to their business. Another
threat to horseshoe crabs is climate change.
As water temperature and sea level rises it has been correlated to have
negative effects on the distribution and reproduction rate of horseshoe crabs. Horseshoe crab eggs are a very important part
of the food web. Around only 10% of the
eggs laid hatch. This is because many of
the shore birds eat the eggs, and the effects of a declining horseshoe crab
population would scale through all the tropic levels.
Not only do horseshoe crabs provide ecosystem benefits, but
also have uses for biomedical research. In
the 1960’s Dr. Frederik Bang discovered that when he injected bacteria into the
horseshoe crab large amounts of clotting occurred. It was later discovered by Dr. Jack Levin
that the clotting was due to the presence of endotoxins produced by the
bacteria. Horseshoe crabs’ blood is a
hemolymph based off of copper which makes it blue. Since horseshoe crabs have evolved so long
ago, they have a very primitive immune system.
This primitive immune system evolved to be sensitive to endotoxins. This endotoxin was believed to have been
expressed in cyanobacteria millions of years ago. Horseshoe crab blood is used to test the
purity of drugs and implants. In the
presence of bacteria or endotoxins the blood coagulates and localizes around
the area of impurities. This is because
horseshoe crabs have an open circulatory system and wall off the infected areas
to stop the infection from spreading.
Biomedical companies use a technique called Limulus
Amebocyte Lysate (LAL) which uses the horseshoe crab hemolymph to detect the
presence of gram negative microbes.
Laboratories use LAL tests on human injectables such as insulin. These medications cannot exceed the test
limits set by the FDA. LAL tests are
also used on artificial implants such as kidneys and heart valves. LAL test provide a quick and sure way to
determine if the medication or device is sterile.
The medical products are placed in to a reconstituted test
tube of LAL. If the LAL coagulates then
the batch of product is contaminated and must be thrown away. A wide array of biomedical products that
people use every day is tested in this manner.
Every shot you have received has past this test to make sure you would
not get sick from contaminated medications.
To produce LAL horseshoe crabs must be caught and
bleed. A sterile needle is inserted into
the animal and the blood is collected.
It is then centrifuged to separate the amoebocytes from the liquid
plasma and then freeze dried for distribution.
This process, while not perfect, has a 10% mortality rate for the
horseshoe crabs. It has been estimated
that a quart of LAL is worth $15,000.
The high cost and need is leading researchers to isolate and clone the
toxin detecting gene. If this is
possible, LAL can be produced without harming the horseshoe crabs.
The value that these horseshoe crabs provide to the
biomedical community is invaluable. But
so is the value of the shellfish to the fishermen of the New England
coast. Horseshoe crabs are most commonly
used as bait by these fishermen and are now being regulated on the amount and
size of horseshoe crabs they are able to collect. Horseshoe crabs are used to bait traps for
eels and conch, which is an extremely profitable business itself. This single species is being fought for by
three different groups; the fisheries, biomedical, and environmentalists. All three of these groups what something
different from this single species.
Now with the threat of bioterrorism, the LAL tests are used
even more. All vaccines and other
injectable medications are thoroughly tested for contamination intentional or
not. With these new demands the
horseshoe crab biomedical field needs a larger supply of LAL. The current policies and processes that the
biomedical companies use still kill 10% of the horseshoe crabs used but could
be much higher once placed back into the wild.
Current research is looking for alternative ways to produce LAL due to
the increasing demand and decreasing population of horseshoe crabs. Only now are researchers tagging horseshoe
crabs and tracking their locations to find effective ways to manage their
populations.
But not only do the three groups, fisheries, biomedical, and
environmentalists have a hand in the decline of the horseshoe crab
populations. After doing some genetic research,
evidence suggests that climate affects horseshoe crab distribution and
interbreeding. Genetic diversity is the
basis of a stable and sustainable population.
A study done in 2005 determined that male horseshoe crabs migrated but
female horseshoe crabs did not. This
could lead to local extinctions if the males of one area all left. This study also provides information that
could lead to new conservation methods. Restriction
on the number of females captured could help keep populations present in all
areas, as well as the relocation of males from different areas to keep the
genetic diversity high between all populations.
As more research is done and the more we learn about horseshoe crabs,
the better we will be able to keep them around and available for all those who
depend on them.
No comments:
Post a Comment